Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.620
-0.060 (-3.57%)
Mar 30, 2026, 1:10 PM EDT - Market open
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $276.08 million as of March 30, 2026. Its market cap has increased by 36.14% in one year.
Market Cap
276.08M
Enterprise Value
107.55M
1-Year Change
36.14%
Ranking
Category
Stock Price
$1.62
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $276.08M, an increase of 174.83%. That is a compound annual growth rate of 21.19%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 27, 2026 | 286.31M | 2.11% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Armata Pharmaceuticals | 306.62M |
| Ovid Therapeutics | 303.31M |
| Bicycle Therapeutics | 300.44M |
| Cabaletta Bio | 298.34M |
| NovaBridge Biosciences | 292.84M |
| NervGen Pharma | 291.52M |
| SAB Biotherapeutics | 270.56M |
| ALX Oncology Holdings | 268.48M |